GUBMENTPlain talk · policy frontier
Filings / Drugs / Sources / §8 Findings: Civil Society & Coalition
GBMT-8 · Research record · No. 8

§8 Findings: Civil Society & Coalitions

drugs/research/ws08-findings.md
This is a working research document from the drugs filing, published as written — including the parts later corrected. It is the underlying record for Whitepaper No. 8, not a summary of it.

Date: 2026-08-03. Fault-line map, funder/advocacy classification per the project's established discipline.

Fault-line summary (the workstream's headline finding)

The real disagreements in US drug policy do not reduce to a simple pro- vs. anti-enforcement axis:

  1. Harm reduction vs. recovery-first — a rupture within the anti-punishment coalition, not a left-right fight. Both sides oppose criminalization; they disagree on whether continued drug use should be accommodated (harm reduction) or whether public resources/housing should condition on abstinence (recovery-first). San Francisco's 2025–2026 Recovery First ordinance fight is the clearest live instance — recovery-community members (including Supervisor Matt Dorsey, himself in recovery) against a coalition of DPA, NHRC, Coalition on Homelessness, and LGBTQ advocacy groups.
  2. Funding-model politics: foundation-dependent vs. government-grant-dependent advocacy. DPA/NHRC run on private foundation money (Open Society/Open Philanthropy-adjacent) and are structurally exposed to donor fatigue — DPA cut staff from ~70 to ~50 in 2021, before the Oregon backlash even hit. CADCA and recovery-community organizations run substantially on federal/state grants (Drug-Free Communities program, SAMHSA, opioid settlement funds) and are exposed to appropriations politics instead. This shapes which actors can credibly claim independence from politics.
  3. Sheriffs vs. DAs, and within DAs, progressive vs. traditional — not a uniform law-enforcement bloc. The Oregon State Sheriffs' Association split from the state's chiefs and DA association over the resource-intensiveness of a deflection mandate. Nationally, DA offices split visibly enough (Gascón and Price recalled in 2024; Brooklyn/Manhattan progressive diversion programs continuing) that "law enforcement's position" cannot be stated as singular. National law-enforcement association positions on safe consumption sites specifically (National Sheriffs' Association, FOP, IACP, NDAA) could not be verified despite repeated targeted searches — flagged as a genuine gap, not filled in with plausible-sounding claims.
  4. Local visible-disorder politics vs. national mortality-data politics — empirically separable. Both the Oregon and San Francisco reversals were driven substantially by donor-funded local coalitions responding to visible/lived disorder, on a faster and more locally-contingent timeline than the underlying academic dispute over M110's actual overdose effect (§9's finding). The "was decriminalization a policy failure" question and "did the coalition break politically" question are separable — the coalition broke regardless of how the mortality-data dispute resolves.

Key actors, funding, and data-vs.-advocacy classification

San Francisco and Oregon as the two documented realignment cases

San Francisco: The Chesa Boudin recall (June 2022) was driven by narratives around retail theft and under-prosecution, not drug policy per se — but it installed a more enforcement-oriented DA and opened an 18-month arc in which Mayor London Breed, who had championed overdose prevention sites in 2021, pivoted to closing the unsanctioned "Tenderloin Center" (Dec. 2022) and proposing conditioning cash assistance on treatment participation (Sept. 2023). Under Mayor Daniel Lurie (2025), the reversal continued institutionally, culminating in Supervisor Dorsey's Recovery First ordinance (signed July 29, 2026, 7-4, over formal DPA/NHRC opposition). The San Francisco AIDS Foundation publicly warned the shift could push some users from smoking to injecting — a direct harm-reduction-sector rebuttal worth carrying into any §10 discussion of political sequencing.

Oregon: A well-funded opposing coalition (Nike co-founder Phil Knight, Columbia Sportswear CEO Tim Boyle, and others — $700K to qualify a repeal ballot initiative) achieved its goal without going to the ballot once the legislature passed HB 4002 (51-7). The pro-decriminalization defense coalition (Oregonians for Safety and Recovery) explicitly included ACLU and racial-justice organizations beyond drug-policy specialists — meaning the 2024 defeat was a broader coalition loss, not solely a drug-policy-organization loss.

Caveat on generalizing: the "broader pattern of Democratic-aligned local governments retreating from harm reduction" claim is suggestive from these two cases, not established across a wider sample (Seattle, Philadelphia, NYC were out of scope here).

Implications for §10/§11

Confidence: Moderate

National funding figures for DPA, NHRC, and SAM are well-sourced to 990 filings via watchdog/journalism intermediaries. San Francisco and Oregon's organizational dynamics are strongly evidenced with named organizations and dates. Capped at moderate because national law-enforcement-association positions on safe consumption sites specifically could not be verified, several sources used carry their own advocacy slant (flagged explicitly per claim), and the "broader pattern" claim rests on only two case studies.

← All Drugs research documents Sources digest Read the whitepaper